HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

<p>Abstract</p> <p>Background</p> <p>The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is low, prompting interest in targeted molecular therapies. We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in this histologic subtype of ovari...

Full description

Bibliographic Details

Main Authors:	Swenerton Kenneth D, Kalloger Steve E, Köbel Martin, Adamiak Anna, Ronnett Bridgett M, Vang Russell, Wiegand Kimberly C, McAlpine Jessica N, Huntsman David G, Gilks C, Miller Dianne M
Format:	Artigo
Language:	Inglês
Published:	BMC 2009-12-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/9/433
Tags:	Add Tag No Tags, Be the first to tag this record!